Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children

NCT01195779 PHASE2 TERMINATED Results posted

The purpose of this observer-blind study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' influenza vaccine GSK2584786A in healthy children 6 to 35 months of age.

Details

Lead sponsor	GlaxoSmithKline
Phase	PHASE2
Status	TERMINATED
Enrolment	4
Start date	Thu Sep 30 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Mar 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Influenza
• Influenza Vaccines

Interventions

• GSK Bio's influenza vaccine GSK2584786A, different formulations
• GSK Bio's influenza vaccine GSK2321138A
• Fluarix™

Countries

Spain